Document is current
Any future updates will be listed below
-
Authors
Schmidt, Richard https://orcid.org/0000-0003-3611-0124
Starke, Andreas
Bednarz, Natalie
Then Bergh, Florian https://orcid.org/0000-0001-8604-8408
-
Funding
Funding for this research was provided by:
Universität Leipzig
- License Information
-
More Information
Article History
Accepted: 13 February 2025
First Online: 6 March 2025
Declarations
:
: This study was conducted in accordance with guidelines of the Declaration of Helsinki and was approved by the institutional review board of the Medical Faculty of Leipzig University, Leipzig, Germany (reference number 063/23-ek). Written informed consent was obtained from all participants. The study was registered in the German Clinical Trial Register (reference number DRKS00031556).
: RS has received travel grants from Alexion Pharma Germany GmbH, Hanns Martin Schleyer Foundation, Congress of the European Committee for Treatment and Research in Multiple Sclerosis, and the German Neurological Society. AS has nothing to declare. NB has nothing to declare. FTB has received, over his academic career, research support and travel grants to attend scientific meetings, through his institution, from the German Science Fund (DFG), German Federal Ministry of Education and Science (BMBF), Bayer-Schering, Diamed, Fresenius, Merck, Novartis, Pfizer, Roche, Sanofi and Teva; speaker fees and compensation for advisory boards from Actelion, Alexion, Bayer, Biogen, CSL Behring, Fresenius, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda and Teva; none were related to this work.
